Real-world effectiveness of sodium-glucose cotransporter-2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria.
CKD
SGLT2 inhibitors
eGFR slope
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
28 Apr 2024
28 Apr 2024
Historique:
revised:
05
04
2024
received:
23
02
2024
accepted:
12
04
2024
medline:
29
4
2024
pubmed:
29
4
2024
entrez:
29
4
2024
Statut:
aheadofprint
Résumé
To examine the renal effects of sodium-glucose cotransporter-2 (SGLT2) inhibition among non-diabetic individuals with chronic kidney disease (CKD) in a real-world setting. We collected de-identified data on adults without diabetes and with an estimated glomerular filtration rate (eGFR) of 25-60 mL/min/1.73 m Of a total of 354 participants with CKD, without diabetes, who received SGLT2 inhibitors and were followed for a median of 527 days, the mean age was 72.8 ± 11.8 years, 26% were female, and 91% used renin-angiotensin system blockade. The mean eGFR was 45.4 ± 9.5 mL/min/1.73 m In a real-world study of primarily older non-diabetic adults with CKD, SGLT2 inhibition was associated with a slower rate of kidney function decline, regardless of baseline UACR level.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : AstraZeneca
Informations de copyright
© 2024 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
Heerspink HJ, Stefánsson BV, Correa‐Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436‐1446.
EMPA‐Kidney Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117‐127.
Grams ME, Sang Y, Ballew SH, et al. Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: an individual participant meta‐analysis of observational data. J Am Soc Nephrol. 2019;30(9):1746‐1755.
Levey AS, Gansevoort RT, Coresh J, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis. 2020;75(1):84‐104.
Inker LA, Collier W, Greene T, et al. A meta‐analysis of GFR slope as a surrogate endpoint for kidney failure. Nat Med. 2023;29(7):1867‐1876.
Inker LA, Heerspink HJ, Tighiouart H, et al. GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta‐analysis of treatment effects of randomized controlled trials. J Am Soc Nephrol. 2019;30(9):1735‐1745.
McEwan P, Boyce R, Sanchez JJ, et al. Extrapolated longer‐term effects of the DAPA‐CKD trial: a modelling analysis. Nephrol Dial Transplant. 2023;38(5):1260‐1270.
Heerspink HJ, Jongs N, Chertow GM, et al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA‐CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):743‐754.
Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379(9811):165‐180.
Sundström J, Bodegard J, Bollmann A, et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2.4 million patients from 11 countries: the CaReMe CKD study. Lancet Reg Health Eur. 2022;20:100438.
Chodick G, Heymann AD, Shalev V, Kookia E. The epidemiology of diabetes in a large Israeli HMO. Eur J Epidemiol. 2003;18:1143‐1146.
Schwandt A, Denkinger M, Fasching P, et al. Comparison of MDRD, CKD‐EPI, and Cockcroft‐Gault equation in relation to measured glomerular filtration rate among a large cohort with diabetes. J Diabetes Complications. 2017;31(9):1376‐1383.
Hananel R, Fishman R, Malovicki‐Yaffe N. Urban diversity and epidemic resilience: the case of the COVID‐19. Cities. 2022;122:103526.
Wanner C, Heerspink HJ, Zinman B, et al. Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA‐REG OUTCOME trial. J Am Soc Nephrol. 2018;29(11):2755‐2769.
Levin A, Stevens PE, Bilous RW, et al. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1‐50.
Melsom T, Norvik JV, Enoksen IT, et al. Sex differences in age‐related loss of kidney function. J Am Soc Nephrol. 2022;33(10):1891‐1902.
Hirst JA, Taal MW, Fraser SD, et al. Change in glomerular filtration rate over time in the Oxford renal cohort study: observational study. Br J Gen Pract. 2022;72(717):e261‐e268.
Yu Z, Rebholz CM, Wong E, et al. Association between hypertension and kidney function decline: the atherosclerosis risk in communities (ARIC) study. Am J Kidney Dis. 2019;74(3):310‐319.
George LK, Koshy SK, Molnar MZ, et al. Heart failure increases the risk of adverse renal outcomes in patients with normal kidney function. Circ Heart Fail. 2017;10(8):e003825.
Mullens W, Damman K, Testani JM, et al. Evaluation of kidney function throughout the heart failure trajectory–a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22(4):584‐603.
Chang AR, Grams ME, Ballew SH, et al. Adiposity and risk of decline in glomerular filtration rate: meta‐analysis of individual participant data in a global consortium. BMJ. 2019;364:k5301.
Greene T, Ying J, Vonesh EF, et al. Performance of GFR slope as a surrogate end point for kidney disease progression in clinical trials: a statistical simulation. J Am Soc Nephrol. 2019;30(9):1756‐1769.
Lees JS, Mark PB. GFR slope as a surrogate marker for future kidney failure. Nat Rev Nephrol. 2023;19(10):625‐626.
Kornowski R, Orvin K. Current status of cardiovascular medicine in Israel. Circulation. 2020;142(1):17‐19.